Refine your search

by
industry

Intercell has acquired Iomai for $189 million, in a deal motivated by the Austrian company's desire to gain ownership of Iomai's traveler's diarrhea vaccine and transdermal delivery technology. With the potential to deliver both vaccine and adjuvant, independently, through Iomai's transdermal patch, Intercell's development of its proprietary adjuvant IC31 may also benefit from the technology.

Published By Datamonitor

Thanks to a new deal with Intercell, Novartis is set to gain access to several vaccine candidates, including those for the prevention of pneumonia in elderly and infants, and hospital-acquired Pseudomonas. After several agreements with other companies and the acquisition of Chiron in 2006, it appears Novartis is on its way to becoming a major infectious diseases player.